Drugs Made In America Acquisition Corp. (DMAA): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$539.2K

Year ended 2025-12-31

-$517.1K

Trailing 12 months to 2026-06-30

Period ended	Operating Cash Flow	Change YoY	Source filing
2025-12-31	-$539.2K	n/a	2026-04-15, From 2025-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Blank Checks), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
Drugs Made In America Acquisition Corp. (DMAA)	2025-12-31	-$539.2K	n/a
Fifth Era Acquisition Corp I (FERA)	2025-12-31	-$890.6K	n/a
Archimedes Tech SPAC Partners II Co. (ATII)	2025-12-31	-$739.0K	n/a
Roman DBDR Acquisition Corp. II (DRDB)	2025-12-31	-$1.29M	n/a
Sizzle Acquisition Corp. II (SZZL)	2025-12-31	-$600.8K	n/a
Cal Redwood Acquisition Corp. (CRAQ)	2025-12-31	-$446.5K	n/a
Jackson Acquisition Co II (JACS)	2025-12-31	-$427.6K	n/a
CSLM Digital Asset Acquisition Corp III, Ltd (KOYN)	2025-12-31	-$770.1K	n/a
Aldel Financial II Inc. (ALDF)	2025-12-31	$9.42M	n/a

Compare DMAA, FERA, ATII, DRDB side by side · Screen every company in Blank Checks ↗